immuno-oncology

Genenta Science (GNTA) announced a $15.0 million registered direct offering on October 27, 2025, involving 4,285,715 American Depositary Shares (ADSs) sold to institutional investors at $3.50 per ADS. Maxim Group LLC and Rodman & Renshaw LLC acted as placement agents. The offering is expected to close around October 28, 2025, with net proceeds intended for working capital and general corporate purposes, potentially advancing clinical trials of its Temferon technology. The offering is being made under a shelf registration statement previously filed with the SEC.

Portage Biotech Inc. (PRTG) announced its continued listing compliance on the Nasdaq Capital Market, as confirmed by the Nasdaq. The immuno-oncology firm focuses on developing novel biologics to harness the immune system against cancer. This release contains forward-looking statements subject to risks and uncertainties, with actual results potentially differing from projections.